NCT04028115View on ClinicalTrials.gov

Bone Healing During Ninlaro Exposure

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 24, 2019

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Ixazomib

Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.

Trial Locations (1)

5000

Odense University Hospital, Odense

All Listed Sponsors
lead

Thomas Lund

OTHER

NCT04028115 - Bone Healing During Ninlaro Exposure | Biotech Hunter | Biotech Hunter